{"id":359456,"date":"2023-11-22T13:25:00","date_gmt":"2023-11-22T18:25:00","guid":{"rendered":"https:\/\/platohealth.ai\/investigating-industry-involvement-in-modern-clinical-trials\/"},"modified":"2023-11-24T02:14:38","modified_gmt":"2023-11-24T07:14:38","slug":"investigating-industry-involvement-in-modern-clinical-trials","status":"publish","type":"post","link":"https:\/\/platohealth.ai\/investigating-industry-involvement-in-modern-clinical-trials\/","title":{"rendered":"Investigating Industry Involvement in Modern Clinical Trials","gt_translate_keys":[{"key":"rendered","format":"text"}]},"content":{"rendered":"
<\/div>\n

Study aims to find ways industry gets involved in the most influential clinical trials, and how transparent these trials are. <\/em><\/p>\n

\n
\n

In a study published earlier this month by JAMA, <\/em>the authors aimed to discover how the pharmaceutical industry gets involved in the most influential modern clinical trials and how they fare in terms of transparency. Crediting the major impact of these clinical trials on medical practice, the authors believed that it was important to evaluate the extent of industry involvement and the use of transparency practices in such studies published in the last few years.1<\/sup><\/p>\n

In order to find a sufficient answer, the study relied on a meta-research assessment consisting of 600 randomized and nonrandomized clinical trials published in 2019 or later. Trials that attracted the highest number of number of citations in Scopus as of December 2022 were selected for analysis, occurring from March to September of this year. Key points included industry involvement, transparency commitments, funding and conclusions, data sharing practices, COVID-19 trials, and improvement areas.1<\/sup><\/p>\n

Results of the study are summarized below.<\/p>\n

Transparency features<\/strong>:<\/p>\n